I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Rheumatoid Arthritis and Eye Inflammation: Protecting Your Vision
How Rheumatoid Arthritis Affects the Eyes
RA is driven by an immune system that mistakenly attacks the body's own tissues. This same inflammatory process can affect multiple structures within the eye, often causing a range of complications that vary in severity.
In RA, inflammatory immune cells and proteins called immune complexes can infiltrate the tissues of the eye just as they affect joints. This can damage delicate eye structures if not recognized and treated early. Eye involvement can appear at any stage of RA, and in some patients, an eye condition may be the first sign that an autoimmune disease is present.
RA can affect several parts of the eye, each causing different symptoms and requiring different treatment approaches.
- Lacrimal glands: inflammation here reduces tear production, leading to dry eye disease
- Episclera: the thin layer between the sclera and conjunctiva can become inflamed, a condition called episcleritis
- Sclera: the white outer wall of the eye can develop scleritis, a deeper and more serious form of inflammation
- Uvea: the iris and ciliary body can become inflamed, a condition called anterior uveitis
- Cornea: the clear front surface of the eye can develop thinning at its edges, known as peripheral ulcerative keratitis
Dry eye disease is the most common ocular complication of RA, often occurring as part of a related condition called secondary Sjogren syndrome, in which immune activity reduces moisture-producing gland function throughout the body.
RA is the most common systemic disease associated with scleritis. Scleritis can occur at the front of the eye (anterior) or the back (posterior) and may present as diffuse redness, a raised nodule, or in its most severe form as necrotizing scleritis, in which scleral tissue begins to break down. This form can lead to scleral thinning and, in advanced cases, perforation of the eye wall. When scleritis develops in a person with RA, it often signals active systemic disease and requires treatment that goes well beyond eye drops alone.
Risk Factors for Ocular Complications
Eye involvement can occur at any point during the course of RA, but certain patient characteristics are associated with a greater likelihood of developing ocular complications.
Women develop RA more frequently than men and accordingly make up the majority of those affected by RA-related eye disease. Patients with seropositive RA, meaning those who test positive for rheumatoid factor or anti-cyclic citrullinated peptide (anti-CCP) antibodies, face a higher risk of extra-articular complications. Extra-articular means the disease affects parts of the body beyond the joints, and the eyes are among the most commonly involved.
The duration and severity of RA are among the strongest predictors of eye complications. Patients with poorly controlled or longstanding disease are more vulnerable. Those who already have other extra-articular manifestations of RA, such as rheumatoid nodules, vasculitis (inflammation of blood vessels), or lung involvement, are at particularly elevated risk for serious conditions like peripheral ulcerative keratitis and necrotizing scleritis.
Hydroxychloroquine is widely used in RA management because of its anti-inflammatory properties and generally favorable safety profile. However, long-term use can lead to retinal toxicity, a form of damage to the light-sensing cells at the back of the eye. The risk is higher with longer duration of use, higher daily doses relative to body weight, and the presence of kidney disease, which affects how the drug is processed by the body. Corticosteroids, another class of medication often used during RA flares, can contribute to elevated eye pressure and an increased risk of cataracts with prolonged use.
Recognizing the Symptoms
The symptoms of RA-related eye disease vary depending on which structure is affected. Knowing what to look for, and how to distinguish a mild symptom from an urgent one, can make a meaningful difference in outcomes.
Dry eye disease is the most common eye complaint among RA patients. Symptoms include a gritty or sandy sensation in the eye, burning, excessive tearing (a reflex response to dryness), and blurred vision that briefly improves with blinking. Symptoms often fluctuate through the day and tend to worsen in dry, windy, or air-conditioned environments. Severe dry eye can cause small breaks in the cornea's surface, a condition called corneal epithelial breakdown, which raises the risk of infection.
Episcleritis causes sectoral redness and mild tenderness that typically resolves on its own within a few weeks. Scleritis causes a deeper, more intense redness with a characteristic boring or throbbing pain that may radiate to the forehead and temple. This pain often worsens at night and can disrupt sleep. Anterior uveitis causes redness, pain, light sensitivity (photophobia), and blurred vision. Peripheral ulcerative keratitis may appear as a white or hazy crescent at the edge of the cornea, often accompanied by redness and discomfort.
Some symptoms should prompt same-day or next-day evaluation by an eye care provider. Do not wait for a scheduled appointment if you experience any of the following:
- Deep, boring eye pain that worsens at night or disrupts sleep
- Significant eye redness that does not improve with artificial tears
- Sudden or progressive decrease in vision
- New onset of light sensitivity
- A white opacity or visible haze at the edge of the cornea
These symptoms can indicate scleritis, peripheral ulcerative keratitis, or uveitis, all of which require prompt treatment to prevent serious vision loss.
Diagnosis and Testing
Diagnosing and monitoring RA-related eye disease involves a combination of clinical examination and specialized imaging. Early and accurate diagnosis makes treatment more effective and helps prevent lasting damage.
A thorough eye examination for a patient with RA assesses the tear film, the surface of the cornea, the sclera, the anterior chamber (the fluid-filled space inside the front of the eye), and the retina. Slit-lamp examination, a magnified inspection using a specialized microscope, can identify signs of scleritis, episcleritis, uveitis, and corneal changes. Staining dyes applied to the eye surface help evaluate the severity of dry eye disease. Dilated examination of the back of the eye allows us to check for posterior scleritis or retinal changes.
Advanced imaging tools provide detailed, objective information that supplements the clinical examination and helps track changes over time.
- Anterior segment OCT (optical coherence tomography): measures corneal thickness in patients with suspected peripheral ulcerative keratitis
- B-scan ultrasonography: uses sound waves to detect scleral thickening or fluid behind the eye, which can confirm posterior scleritis
- Macular OCT and automated visual field testing: the standard tools used for hydroxychloroquine retinal toxicity screening
Together, these tests allow our team to monitor treatment response and detect changes before they become harder to manage.
The American Academy of Ophthalmology recommends that patients beginning hydroxychloroquine have a baseline eye examination within the first year of starting the medication. Annual screening is then recommended beginning after five years of use. Screening includes OCT of the macula and automated visual field testing using the 10-2 protocol, which focuses on the central area of the visual field most affected by this type of toxicity. Patients with kidney disease or other risk factors may need earlier or more frequent screening. When early signs of toxicity are detected, our team will communicate with your rheumatologist about potential medication adjustments.
Treatment Approaches
Treatment for RA-related eye disease is matched to the specific condition present, its severity, and the patient's overall health. A coordinated approach between ophthalmology and rheumatology typically leads to the best outcomes.
For mild dry eye, the foundation of treatment is frequent use of preservative-free artificial tears throughout the day and a lubricating ointment at bedtime. For moderate to severe dry eye, prescription anti-inflammatory eye drops such as cyclosporine or lifitegrast can help reduce ocular surface inflammation and improve tear production. Small plugs inserted into the tear drainage channels, called punctal plugs, help retain moisture on the eye surface. Environmental adjustments such as using a humidifier or wearing moisture-chamber glasses in dry conditions can also provide meaningful relief. Treating the underlying RA inflammation effectively often improves dry eye symptoms as well.
Mild cases of anterior uveitis and episcleritis may respond to topical corticosteroid eye drops and oral nonsteroidal anti-inflammatory drugs. Scleritis typically requires systemic treatment. Oral corticosteroids are used initially to bring inflammation under control, followed by longer-term steroid-sparing immunosuppressive agents such as methotrexate for ongoing management. For severe or treatment-resistant cases, biologic medications including tumor necrosis factor (TNF) inhibitors and other targeted immune agents may be incorporated into the treatment plan. These decisions are made collaboratively between the patient's rheumatologist and ophthalmologist.
Peripheral ulcerative keratitis is treated as a medical emergency. Because the cornea can thin and ultimately perforate if left untreated, systemic immunosuppressive therapy must be started urgently. Topical treatment alone is not sufficient. In cases where significant corneal thinning has already occurred, tissue adhesive (a specialized medical glue) or a corneal graft may be needed to preserve the structural integrity of the eye. Long-term immunosuppression is typically required to prevent recurrence, and close follow-up with both ophthalmology and rheumatology is essential throughout treatment.
If screening detects early signs of hydroxychloroquine retinal toxicity, the most important intervention is stopping the medication in coordination with the rheumatologist, who will identify alternative approaches for managing RA. Early detection, before significant photoreceptor damage has occurred, offers the best chance of preserving vision. Once retinal damage from hydroxychloroquine has developed, it does not reverse, which is why consistent adherence to the recommended screening schedule is so critical for patients taking this medication long-term.
Managing RA-Related Eye Disease Over Time
RA-related eye conditions often require ongoing attention rather than a single course of treatment. Understanding what to expect can help patients stay engaged in their care and recognize changes that warrant attention.
Managing eye disease in RA works best as a team effort. The rheumatologist oversees the systemic disease and prescribes immunosuppressive and biologic therapies. The ophthalmologist or retina specialist monitors and treats eye-specific complications. When both providers communicate openly, decisions about medication changes can account for both joint and eye disease activity. Patients play an important role by keeping each provider informed about medications prescribed by the other and by reporting any new symptoms without delay.
Consistent use of artificial tears and attention to environmental factors helps manage dry eye between appointments. Patients taking hydroxychloroquine should keep all scheduled screening appointments without delay. Wearing sunglasses with UV protection can ease light sensitivity during periods of active inflammation. Maintaining good overall control of systemic RA activity through prescribed medications also benefits eye health by reducing the inflammatory burden on ocular tissues.
Advances in immunosuppressive and biologic therapies have meaningfully improved outcomes for patients with RA-related eye disease. Most patients with episcleritis and mild scleritis achieve good control with appropriate treatment. Necrotizing scleritis and peripheral ulcerative keratitis carry a more guarded prognosis, but early and aggressive treatment significantly improves outcomes. For patients on hydroxychloroquine, consistent adherence to screening recommendations gives the best opportunity to preserve vision if early retinal changes develop.
Frequently Asked Questions
Here are answers to questions we hear often from patients and referring providers about RA-related eye disease, focused on practical guidance and decision-making.
Yes, recurrence is possible, particularly with scleritis and uveitis. These conditions often mirror the activity of the underlying RA, meaning a flare in joint disease can trigger a flare in eye disease. For this reason, long-term immunosuppressive therapy is often maintained even after the eye condition appears well controlled. If your eye symptoms return between scheduled appointments, contact your eye care provider promptly rather than waiting, since earlier intervention generally leads to better outcomes.
It depends on your specific situation. A general eye care provider can monitor dry eye and episcleritis effectively and can perform hydroxychloroquine screening. However, if you develop scleritis, posterior uveitis, or signs of retinal toxicity, a retina specialist brings additional diagnostic tools and experience managing complex inflammatory conditions. Many patients benefit from a shared-care model in which their general eye care provider and a retina specialist collaborate alongside their rheumatologist.
Stopping the medication eliminates future exposure and prevents additional toxicity from accumulating. However, hydroxychloroquine can remain stored in retinal tissue for months to years after the last dose, and in some patients, subtle retinal changes may continue to progress even after the drug has been discontinued. This is one more reason why detecting toxicity early through regular screening matters so much. Your rheumatologist can help identify alternative medications if hydroxychloroquine needs to be stopped.
Yes, in many cases it can. The eye complications of RA are driven by the same immune activity that damages joints. When systemic disease is well managed through medication, the inflammatory burden on ocular tissues is reduced. Many patients notice improvements in dry eye symptoms and fewer inflammatory episodes affecting the eye when their RA is better controlled overall. This is one reason why close coordination between your rheumatologist and eye care provider benefits both your joints and your vision.
The timeline depends on the type of scleritis. Diffuse or nodular anterior scleritis may cause significant pain but typically does not produce rapid structural damage when treated promptly. Necrotizing scleritis, however, can progress to serious structural damage within weeks if systemic treatment is delayed. Deep, persistent eye pain in a patient with RA should be evaluated as soon as possible. Even if the eye does not appear severely red on the surface, the underlying process may already be causing meaningful damage to the eye wall.
Schedule a Consultation at New England Retina Associates
At New England Retina Associates, our fellowship-trained vitreoretinal specialists serve patients with complex inflammatory eye conditions across Connecticut, offering the diagnostic expertise and advanced imaging needed to protect your vision. Whether you have been referred for retinal monitoring, are overdue for hydroxychloroquine screening, or are experiencing new eye symptoms related to RA, we welcome you to contact any of our four offices to schedule an appointment. We are committed to working alongside your rheumatologist to provide coordinated, expert care tailored to your individual needs.
30 Years of Care & Commitment
